Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 19 Sep 2025
Patients in specialized psychiatric care face a variety of social risks that are intertwined, according to a new study from the University of Eastern Finland published in Nordic Social Work Research. Social risks tend to ...
Read Full NewsAripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.
Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.
In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.
1.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
2.
The main subject is associated with suicide in the United States.
3.
Alkem introduces cetuximab under the trade name Cetuxa in India.
4.
Firefighters who eat better can combat cancer.
5.
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
1.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
2.
Progressive Insights in Hematology in the Digital Era
3.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
4.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
5.
The Rise of Immunotherapy: New Advances in Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
2.
Blood Clotting Disorders Explained
3.
Sickle Cell Disease Explained
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge